ClinicalTrials.gg
RecruitingNCT07827599PearlstoneUpdated Nov 17, 2026

A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants

A Phase 3 interventional study of Baloxavir marboxil and Placebo in Influenza, Human, Respiratory Tract Infections and Post-exposure Prophylaxis, sponsored by Hoffmann-La Roche. Recruiting at 20 sites in China. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 17, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Planned enrollment
13th of 18
325 · median 483
Started
2026
with 1 other
Phase 3
12 of 18
5 open now
Registered
18th of 18
by date
Lead sponsor
7 of 18
Hoffmann-La Roche

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 13th largest by planned enrollment, is one of 2 that started in 2026, is one of 12 in phase 3, and was the 18th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 5 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in participants who are household contacts (HHCs) of participants with influenza (index participants).

03

Conditions studied

  • Influenza, Human
  • Respiratory Tract Infections
  • Post-exposure Prophylaxis

Keywords

  • Influenza
  • Baloxavir Marboxil
  • Household Contacts
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Index Participants (Participants With Influenza Virus Infection):

  • First participant in a household with influenza virus infection in the current influenza season
  • Fewer than 6 HHCs
  • Agreement by all household members to participate in the study and comply with the study protocol for the duration of the study
  • Diagnosed as having influenza with positive rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) result
  • Onset of symptoms within 48 hours or less at time of signing Form (ICF)/Assent Form
  • PCR (-) or antigen test (-) for severe acute respiratory virus-coronavirus 2 (SARS-CoV-2) using point-of-care or local laboratory test

HHCs of Index Participants:

  • Lived with the index participant for 48 hours or more prior to informed consent/assent
  • Meet all the following criteria and are judged not to have influenza virus infection by the investigator: body temperature (tympanic) \<37.5 degrees Celsius (°C); no influenza-like symptoms (cough, sore throat, headache, nasal discharge/nasal congestion, feverishness or chills, muscle or joint pain, or fatigue) at screening; negative RIDT or PCR result for influenza
  • For participants 12 years of age or older, ability to evaluate influenza symptoms by using a participant influenza symptoms diary; For participants under 12 years of age, capability of parents/caregivers to evaluate influenza symptoms by using a participant influenza symptoms diary
  • PCR (-) or antigen test (-) for SARS-CoV-2 using point-of-care or local laboratory test

Exclusion criteria

Exclusion Criteria:

HHCs of Index Participants:

  • Diagnosed with influenza during the current influenza season
  • Unable to live with the index patient from screening until Day 10
  • Live with a household member who has any influenza-like symptom(s) other than the index participant on the day of screening
  • Live with household members other than the index participant who was diagnosed with or strongly suspected to have influenza during the current influenza season
  • Have any underlying diseases requiring systemic (oral or injection), or nasal treatment of antipyretics/analgesics, , or agents
  • Immunocompromised
  • Use of any medications with anti-influenza effect within 30 days prior to screening
  • Known allergy and/or history of significant intolerance against baloxavir marboxil
  • Exposure to an drug within 30 days or 5 half-lives of the drug prior to screening, whichever is longer

Note: Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
325 participants (estimated)

Study arms

  • Experimental
    Baloxavir Marboxil

    HHCs will receive baloxavir marboxil according to their body weight as outlined in the protocol.

    Drug: Baloxavir marboxil

  • Placebo comparator
    Placebo

    HHCs will receive baloxavir marboxil matching placebo according to their body weight as outlined in the protocol.

    Drug: Placebo

  • No intervention
    No Intervention

    Index participants will not receive any study treatment but will continue to receive SOC treatment for influenza, as per the local guidelines.

Interventions

  • Baloxavir marboxil will be administered to the HHCs as per the schedule specified in the protocol.

    Also known as: Xofluza; RO7191686

  • DrugPlacebo

    Baloxavir marboxil matching placebo will be administered to the HHCs as per the schedule specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who are Infected With Influenza Virus (Reverse Transcription - Polymerase Chain Reaction [RT-PCR] Positive), and Present With Fever and at Least one Respiratory Symptom

    Time frame: From Day 1 up to Day 10

Secondary outcomes

  1. Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive), and Present With Fever or at Least one Influenza Symptom (Respiratory or Systemic)

    Time frame: From Day 1 up to Day 10

  2. Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive) Regardless of Body Temperature or Influenza Symptoms

    Time frame: From Day 1 up to Day 10

  3. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Day 21

07

Study locations

20 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 6 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 18, 2026
StartActual
Oct 16, 2026was Sep 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
20 sites added — first site in China
Show 20 added (20 China)
  • Zhujiang Hospital, Southern Medical University · Guangzhou, China
  • Mianyang Central Hospital · Mianyang, China
  • The First People's Hospital of Changde · Changde, China
  • Huizhou Central People's Hospital · Huizhou, China
  • Ningbo No.2 Hospital · Ningbo, China
  • Sanmenxia Central Hospital · Sanmenxia, China
  • Huashan Hospital Affiliated to Fudan University · Shanghai, China
  • Xiamen Maternal and Child Health Hospital · Xiamen, China
  • Affiliated Hospital of Zunyi Medical University · Zunyi, China
  • Peoples Hospital of Hunan Province · Changsha, China
  • Jiujiang No.1 People's Hospital · Jiujiang, China
  • Hebei Petro China Central Hospital · Langfang, China
  • Liuzhou People's Hospital · Liuzhou, China
  • Luoyang Central Hospital · Luoyang, China
  • Ningbo Women and Children's Hospital · Ningbo, China
  • Pingxiang People's Hospital · Pingxiang, China
  • The Third People's Hospital of Hainan Province · Sanya, China
  • The First Affiliated Hospital, Shaoyang University · Shaoyang, China
  • Shijiazhuang People's Hospital · Shijiazhuang, China
  • Weifang No.2 People's Hospital · Weifang, China
across 2 updates, Oct 22, 2026 – Nov 17, 2026
Start date
Sep 22, 2026→Oct 16, 2026 (actual)
Oct 22, 2026
Show all 2 updates
  1. Nov 17, 2026
    12 sites added
    Show 12 added (12 China)
    • Affiliated Hospital of Zunyi Medical University · Zunyi, China
    • Peoples Hospital of Hunan Province · Changsha, China
    • Jiujiang No.1 People's Hospital · Jiujiang, China
    • Hebei Petro China Central Hospital · Langfang, China
    • Liuzhou People's Hospital · Liuzhou, China
    • Luoyang Central Hospital · Luoyang, China
    • Ningbo Women and Children's Hospital · Ningbo, China
    • Pingxiang People's Hospital · Pingxiang, China
    • The Third People's Hospital of Hainan Province · Sanya, China
    • The First Affiliated Hospital, Shaoyang University · Shaoyang, China
    • Shijiazhuang People's Hospital · Shijiazhuang, China
    • Weifang No.2 People's Hospital · Weifang, China
    + 1 other change: verification date
  2. Oct 22, 2026
    Not yet recruiting→Recruiting
    8 sites added — first site in China
    Show 8 added (8 China)
    • Zhujiang Hospital, Southern Medical University · Guangzhou, China
    • Mianyang Central Hospital · Mianyang, China
    • The First People's Hospital of Changde · Changde, China
    • Huizhou Central People's Hospital · Huizhou, China
    • Ningbo No.2 Hospital · Ningbo, China
    • Sanmenxia Central Hospital · Sanmenxia, China
    • Huashan Hospital Affiliated to Fudan University · Shanghai, China
    • Xiamen Maternal and Child Health Hospital · Xiamen, China
    Start date Sep 22, 2026→Oct 16, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07827599
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Oct 16, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Roche Pharma (Schweiz) AG Reference Study ID Number: YV46459, https://forpatients.roche.com/
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion